Get the Stockscreener App
9.13
3.18%
-0.30
After Hours:
9.13
Arcus Biosciences Inc stock is traded at $9.13, with a volume of 701.95K.
It is down -3.18% in the last 24 hours and up +12.16% over the past month.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
See More
Previous Close:
$9.43
Open:
$9.35
24h Volume:
701.95K
Relative Volume:
0.67
Market Cap:
$966.73M
Revenue:
$247.00M
Net Income/Loss:
$-249.00M
P/E Ratio:
-2.9547
EPS:
-3.09
Net Cash Flow:
$-267.00M
1W Performance:
-7.50%
1M Performance:
+12.16%
6M Performance:
-29.22%
1Y Performance:
-44.36%
1-Day Range:
$9.061
$9.45
1-Week Range:
$9.061
$10.34
52-Week Range:
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
9.13 | 998.50M | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Arcus Biosciences’ Pancreatic Cancer Drug Quemliclustat Receives Orphan Drug Designation from FDA - Insider Monkey
How does Arcus Biosciences Inc. generate profit in a changing economyPost Market Planner That Work - jammulinksnews.com
What institutional investors are buying Arcus Biosciences Inc. stockPost Market Growth Plan With High Returns - jammulinksnews.com
Will Arcus Biosciences Inc. bounce back from current supportEarly Breakout Entry Point Notifications Sent - metal.it
How many analysts rate Arcus Biosciences Inc. as a “Buy”Advanced Screener Report With Low Risk - jammulinksnews.com
Arcus Biosciences Inc.’s Price Action Aligns with Quant SignalsHigh Yield Stock Screening Results Explained - metal.it
Arcus Biosciences’ SWOT analysis: HIF-2alpha program drives stock outlook - Investing.com
Why is Arcus Biosciences Inc. stock attracting strong analyst attentionTop Growth Ideas To Watch Now - jammulinksnews.com
Arcus Biosciences Inc. Shows Risk Reward Favoring UpsideReal Trader Watchlist of Hot Stocks Released - metal.it
Is it the right time to buy Arcus Biosciences Inc. stockSuperior returns - jammulinksnews.com
When is Arcus Biosciences Inc. stock expected to show significant growthEarnings Report Alerts For Every Investor - jammulinksnews.com
Should I hold or sell Arcus Biosciences Inc. stock in 2025Explosive earning power - jammulinksnews.com
What is Arcus Biosciences Inc. company’s growth strategyMaximize your portfolio’s growth potential - jammulinksnews.com
What are the latest earnings results for Arcus Biosciences Inc.Discover stocks with explosive growth potential - jammulinksnews.com
How volatile is Arcus Biosciences Inc. stock compared to the marketMaximize portfolio growth with strategic plans - jammulinksnews.com
New Product Launches: Will They Boost Arcus Biosciences Inc. Stock in 2025Professional Stock Screener - metal.it
What is the dividend policy of Arcus Biosciences Inc. stockGet daily updates on the hottest stocks - jammulinksnews.com
Arcus Biosciences Inc. Company’s Quarterly Earnings Growth: What the Numbers SayInvestor Favorite Picks - metal.it
How Interest Rate Changes Impact Arcus Biosciences Inc. Stock PerformanceFree Stock Market Beginners Guide - Newser
Arcus Biosciences Inc. Stock Support and Resistance Levels You Should KnowFree Deep Market Trend Analysis - Newser
Bank of New York Mellon Corp Increases Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Is Arcus Biosciences Inc. stock a good hedge against inflationFree Stock Market Insider Analysis - Newser
What drives Arcus Biosciences Inc. stock priceExplosive earnings growth - PrintWeekIndia
Arcus Biosciences shares rise 3.65% intraday after granting new employee options and restricted stock units. - AInvest
Arcus Biosciences Inc. Stock Analysis and ForecastMarket-beating performance - PrintWeekIndia
What analysts say about Arcus Biosciences Inc. stockRapidly growing investment returns - PrintWeekIndia
Is Arcus Biosciences Inc. a good long term investmentRecord-breaking gains - PrintWeekIndia
Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
Gilead and Arcus Biosciences’ Promising Lung Cancer Study: Market Implications - TipRanks
Arizona State Retirement System Purchases 5,010 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Gilead and Arcus Biosciences’ Promising Phase 3 Lung Cancer Study Update - TipRanks
Teacher Retirement System of Texas Has $143,000 Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):